Viridian Therapeutics Inc — Cash Flow (NASDAQ:VRDN) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities -29.78 M-54.58 M-93.84 M-184.17 M-232.32 M276.39 M -228.88 M Cash from investing activities -50.48 M-74.29 M-115.13 M-94.25 M-228.65 M37.56 M 37.56 M Cash from financing activities 101.31 M125.28 M322.24 M225.67 M457.74 M426.74 M 426.74 M Free cash flow -29.82 M-54.92 M-94.64 M-185.07 M-232.83 M275.9 M -229.38 M

Nouvelles

Stifel réitère sa recommandation sur Viridian Therapeutics lors de l’examen de la demande d’autorisation

Stifel reiterates Viridian Therapeutic stock rating on BLA review

Jefferies relève l’objectif de cours de Viridian Therapeutic suite aux progrès des essais

Jefferies raises Viridian Therapeutic stock price target on trial progress

Evercore ISI réitère sa recommandation sur Viridian Therapeutics

Evercore ISI reiterates Viridian Therapeutic stock rating on data conviction

Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates

Le BPA de Viridian Therapeutics a manqué les attentes de 0,10$, le CA en dessous des prévisions

Viridian Therapeutics earnings missed by $0.10, revenue fell short of estimates

MiMedx (MDXG) Q4 Earnings and Revenues Beat Estimates

BB Biotech 2025 : bénéfice en hausse de 660%, prudence pour 2026

Truist réitère sa recommandation sur Viridian Therapeutics avant l’essai